FDA appears open to Moderna's flu vaccine ahead of adcomm

UniQure will submit Huntington's therapy for approval, Eli Lilly buys 4E Therapeutics, and more biotech news HHS drug pricing Obesity Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home Newsletter The Readout FDA appears open to Moderna’s flu vaccine ahead of adcomm UniQure will submit Huntington’s therapy for…

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. Today, one venture capitalist weighs in on the China biotech debate. Let me know if you agree with her or not.

UniQure will submit Huntington’s therapy for approval

The FDA has reversed its opposition to a closely watched experimental treatment for Huntington’s disease, clearing a path for its maker, the biotech company UniQure, to file for U.S. approval, the company said morning.

Continue to STAT+ to read the full story…